Research programme: Alzheimer's disease therapeutics - Oligomerix

Drug Profile

Research programme: Alzheimer's disease therapeutics - Oligomerix

Latest Information Update: 06 May 2016

Price : $50

At a glance

  • Originator OLIGOMERIX
  • Class Antibodies; Small molecules
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 02 May 2016 Oligomerix receives Direct to phase II SBIR grant from National Institute of Aging, National Institutes of Health for small molecule drug development in Alzheimer's disease
  • 30 Jun 2014 Preclinical trials in Alzheimer's disease in USA (unspecified route)
  • 30 Jun 2014 Research programme: Alzheimer's disease therapeutics - Oligomerix is available for licensing as of 30 Jun 2014. www.oligomerix.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top